Bhavna Verma, PhD1, Maria Mancini, PhD1, Angela Davies, PhD1, David Sidransky, PhD2, Amy Wesa, PhD1 and Neal Goodwin, PhD1
1Champions Oncology, USA. 2Johns Hopkins University School of Medicine, USA.
The clinical success of immune checkpoint modulators and development of next-generation immuneoncology (IO) agents underscores the need for robust patient-derived models to evaluate novel therapeutics. The Champions ImmunoGraft® model utilizing humanized NOG mice is an innovative pre-clinical model for assessing the efficacy of IO agents against solid tumors. Improved immunodeficient mouse strains, such as triple transgenic NOG-EXL mice expressing huIL-3 and huGM-CSF, allows for superior HIS development. In this study, we compared human immune lineage development, tumor infiltrating leukocytes, as well as an assessment of tumor response to checkpoint inhibitor in this humanized mouse platform.